Targeting the immune microenvironment in blastic plasmacytoid dendritic cell neoplasm: a genomic perspective

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy originating from precursors of plasmacytoid dendritic cells (pDCs). While normal pDCs are crucial producers of type I interferon (IFN-I) and activators of anti-tumor immunity, BPDCN cells paradoxically lose these functions and create a profoundly immunosuppressive tumor microenvironment (TME).

This systematic review synthesizes recent genomic and molecular insights to detail the intricate connection between the disease's intrinsic landscape and its immune evasion mechanisms, with the goal of informing novel therapeutic strategies.

The genomic architecture of BPDCN is marked by frequent cytogenetic abnormalities and pervasive epigenetic dysregulation, defined by recurrent mutations in Tet methylcytosine dioxygenase 2 (TET2) and Additional sex combs like 1 (ASXL1). Furthermore, the survival of malignant cells is sustained by key oncogenic pathways, including the transcription factor 4 (TCF4)-bromodomain-containing protein 4 (BRD4) network and the high expression of the interleukin-3 receptor alpha chain (CD123). Within the TME, these genomic alterations drive T cell exhaustion, suppress natural killer (NK) cell and macrophage function, and promote the expression of immune checkpoints such as programmed death-ligand 1 (PD-L1), while also establishing an immunosuppressive cytokine milieu rich in interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). The approval of tagraxofusp, the first CD123-targeted therapy, has revolutionized treatment by achieving high response rates and facilitating allogeneic stem cell transplantation (allo-SCT), which remains the only potentially curative option. However, the frequent development of resistance highlights the need for a new paradigm.

Future directions focus on combination therapies that simultaneously address multiple pathways, such as combining CD123-targeted agents with epigenetic modulators or B-cell lymphoma 2 (BCL2) inhibitors like venetoclax to achieve deeper and more durable responses. This integrated approach is essential for advancing precision medicine and improving outcomes for patients facing this challenging neoplasm.